Anne-marie M. Coady
Kingston Upon Hull, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome.
Journal: Frontiers in endocrinology
Published: February 12, 2019
The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome.
Journal: Frontiers in endocrinology
Published: November 04, 2018
The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome.
Journal: Endocrine connections
Published: September 28, 2017
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Journal: BMC endocrine disorders
Published: January 24, 2017
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
Journal: Clinical endocrinology
Published: July 14, 2016
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.
Journal: Clinical endocrinology
Published: June 04, 2016
Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
Journal: Clinical endocrinology
Published: August 17, 2013
Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.
Journal: Diabetes, obesity & metabolism
Published: July 31, 2013
Twin pregnancy with a complete hydatidiform mole and co-existent healthy fetus: unusual case of complete resorption of molar pregnancy.
Journal: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
Published: April 05, 2013
Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity.
Journal: Clinical endocrinology
Published: October 08, 2012
A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease.
Journal: Clinical endocrinology
Published: September 04, 2012
Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome.
Journal: The Journal of clinical endocrinology and metabolism
Published: August 11, 2012
Last Updated: 09/26/2026